Considerations for Statin Therapy in Patients with COVID-19

Pharmacotherapy. 2020 May;40(5):484-486. doi: 10.1002/phar.2397. Epub 2020 May 4.
No abstract available

Keywords: COVID-19; HMG-CoA reductase inhibitor; SARS-CoV; coronavirus infection; statin.

Publication types

  • Letter

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Drug Interactions
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Respiratory Distress Syndrome / drug therapy
  • Respiratory Distress Syndrome / virology
  • SARS-CoV-2

Substances

  • Antiviral Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors